株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

炎症性腸疾患 (IBD) 治療薬の世界市場の予測:2019年~2029年

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

発行 Visiongain Ltd 商品コード 209072
出版日 ページ情報 英文 245 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.96円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
炎症性腸疾患 (IBD) 治療薬の世界市場の予測:2019年~2029年 Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
出版日: 2019年06月21日 ページ情報: 英文 245 Pages
概要

世界の炎症性腸疾患 (IBD) 治療薬市場は、2018年に72億米ドルに達し、そのうちの65%を生物療法が占めました。同市場は2024年までのCAGR (複合年間成長率) で、3.6%の成長が見込まれています。

当レポートでは、世界の炎症性腸疾患 (IBD) 治療薬市場について調査分析し、市場概要、市場力学、市場予測、主要地域の予測、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 炎症性腸疾患 (IBD) 治療薬市場のイントロダクション

  • 炎症性腸疾患 (IBD) とは
  • IBDの分類
  • IBDの症状と診断
  • IBDの原因は多因子
  • 一般的なIBDとは
  • IBDの治療オプションとは
  • IBDの治療目標
  • 治療アルゴリズム
  • IBDの管理

第3章 世界の炎症性腸疾患 (IBD) 治療薬市場:適応別

第4章 世界の炎症性腸疾患 (IBD) 治療薬市場:薬剤分類別

  • IBD治療薬市場
  • 予測
  • 生物療法
  • アミノサリチル酸
  • 抗生物質
  • コルチコステロイド
  • 免疫刺激剤

第5章 炎症性腸疾患 (IBD) 主要治療薬市場の見通し

  • Humira (AbbVie)
  • Remicade (Janssen Biotech)
  • Cimzia (UCB)
  • Tysabri (Perrigo)
  • Asacol (Allergan)
  • Pentasa (Shire)
  • Lialda (Shire)
  • Xifaxan (Valeant)
  • Canasa/Salofalk (Allergan)
  • Apriso (Valeant)
  • Entyvio (武田薬品工業)
  • Simponi (Janssen Biotech)
  • Uceris (Valeant)

第6章 世界の炎症性腸疾患 (IBD) 治療薬市場:流通経路別

第7章 主要国市場:販売の見通し

  • IBD治療薬:主要国市場
  • 米国
  • 日本
  • EU5ヶ国
  • BRIC諸国

第8章 炎症性腸疾患 (IBD) 治療薬のR&Dパイプライン

  • 主な上市薬・パイプライン製品
  • インターロイキン (IL) 阻害剤
  • 細胞接着分子 (CAM) 阻害剤
  • TNFアルファ阻害剤
  • 幹細胞治療、など

第9章 炎症性腸疾患 (IBD) 治療薬産業・市場の定性分析

  • SWOT・STEP分析
  • 市場促進要因
  • 市場抑制要因

第10章 炎症性腸疾患 (IBD) 治療薬市場の主要企業

  • 大企業:収益別
    • AbbVie
    • Janssen Biotech
    • Allergan plc
    • 武田薬品工業
    • Pfizer
    • Novartis AG
    • UCB Pharma S.A.
    • Biogen Inc.
    • Gilead Sciences, Inc.
    • Roche
    • Celgene Corporation

第11章 結論

付録

図表

List of Tables

  • Table 2.1 Differentiating Crohn's Disease and Ulcerative Colitis
  • Table 2.2 Clinical Presentation Crohn's Disease and Ulcerative Colitis
  • Table 2.3 Worldwide Prevalence Rates for IBD, 2017-2018
  • Table 2.4 Worldwide Incidence Rates for IBD, 2017-2018
  • Table 2.5 Geographical Variations in the Incidence of IBD, 2018
  • Table 2.6 Treatment Recommendations for IBD
  • Table 2.7 Medical Approach for IBD Management, 2018
  • Table 2.8 Other Drug Types Used to Treat IBD, 2018
  • Table 2.9 Aminoacylates for IBD Management, 2018
  • Table 2.10 Antibiotics for IBD Management, 2018
  • Table 2.11 Immunomodulators for IBD Management, 2018
  • Table 2.12 Monoclonal Antibodies for IBD Management, 2018
  • Table 2.13 Treatment Protocol for IBD, 2018
  • Table 3.1 Global IBD Drug Market by Indication: Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2017 and 2018
  • Table 3.2 Global IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Drug Class, 2017 and 2018
  • Table 4.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.3 Global IBD Drug Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.4 Global IBD Drug Market Drivers and Restraints 2019-2029
  • Table 4.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.6 Global Biologic Therapies Drivers and Restraints, 2019-2029
  • Table 4.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.8 Global Aminosalicylates Drivers and Restraints, 2019-2029
  • Table 4.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.10 Global Antibiotics Drivers and Restraints, 2019-2029
  • Table 4.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.12 Global Corticosteroids Drivers and Restraints, 2019-2029
  • Table 4.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.14 Global Immunomodulators Drivers and Restraints, 2018-2028
  • Table 5.1 Leading IBD Treatments by Revenue ($m), 2018
  • Table 5.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2019-2029
  • Table 5.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.4 Drivers and Restraints for Humira, 2019-2029
  • Table 5.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.6 Drivers and Restraints for Remicade, 2019-2029
  • Table 5.7 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.8 Drivers and Restraints for Cimzia, 2019-2029
  • Table 5.9 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.10 Drivers and Restraints for Tysabri, 2019-2029
  • Table 5.11 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.12 Drivers and Restraints for Asacol, 2019-2029
  • Table 5.13 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.14 Drivers and Restraints for Pentasa, 2019-2029
  • Table 5.15 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.16 Drivers and Restraints for Lialda, 2019-2029
  • Table 5.17 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.18 Drivers and Restraints for Xifaxan, 2019-2029
  • Table 5.19 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.20 Drivers and Restraints for Canasa, 2019-2029
  • Table 5.21 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.22 Drivers and Restraints for Apriso, 2019-2029
  • Table 5.23 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.24 Drivers and Restraints for Entyvio, 2019-2029
  • Table 5.25 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.26 Drivers and Restraints for Simponi, 2019-2029
  • Table 5.27 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.28 Drivers and Restraints for Uceris, 2019-2029
  • Table 6.1 World Inflammatory Bowel Disease by Distribution Channel Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.1 IBD Drug Revenues ($m) by Leading Country, 2018
  • Table 7.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.3 US IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.4 US IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.5 US IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.6 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.7 Japanese IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.8 Japan IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.9 Japan IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.10 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.11 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.12 German IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.13 German IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.14 German IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.15 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.16 French IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.17 French IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.18 French IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.19 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.20 UK IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.21 UK IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.22 UK IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.23 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.24 Spanish IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.25 Spanish IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.26 Spanish IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.27 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.28 Italian IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.29 Italian IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.30 Italian IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.31 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.32 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.33 Brazilian IBD Drug Market Forecast by Indication: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.34 Brazilian IBD Drug Market Forecast by Drug Class: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.35 Brazilian IBD Drug Market Forecast by Distribution Channel: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.36 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.37 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.38 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2029
  • Table 8.1 Key Patents for marketed and pipeline products
  • Table 8.2 Biologics and biosimilars approved for treatment in IBD
  • Table 8.3 Biologics in the pipeline and their current status
  • Table 8.4 Biosimilars in the pipeline and their current status
  • Table 8.5 Selected IL Inhibitors in Clinical Development, 2018
  • Table 8.6 Selected CAM Inhibitors in Clinical Development, 2018
  • Table 8.7 Selected TNF-a Inhibitors in Clinical Development, 2018
  • Table 8.8 Selected Stem Cell Therapies in Clinical Development, 2018
  • Table 8.9 Selected JAK Inhibitors in Clinical Development, 2018
  • Table 8.10 Selected Toll-like Receptor Agonist in Clinical Development, 2018
  • Table 8.11 Selected Other Classes in Clinical Development, 2018
  • Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market
  • Table 9.2 Social, Technological, Economic and Political Forces on the IBD Drug Market
  • Table 10.1 AbbVie Revenues ($m) and Market Share (%), 2018
  • Table 10.2 Janssen Biotech Revenues ($m) and Market Share (%), 2018
  • Table 10.3 Allergan Revenues ($m) and Market Share (%), 201
  • Table 10.4 Takeda Revenues ($m) and Market Share (%), 2018
  • Table 10.5 Pfizer Revenues ($m) and Market Share (%), 2018
  • Table 10.5 UCB Pharma S.A Revenues ($m) and Market Share (%), 2018
  • Table 10.7 Biogen Inc. Revenues ($m) and Market Share (%), 2018
  • Table 11.1 Global IBD Revenue Forecasts ($m), Market Share (%) by Product Category, 2019, 2024, 2029
  • Table 11.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2019, 2024, 2029
  • Table 11.3 Summary of IBD Market Drivers and Restraints, 2019-2029

List of Figures

  • Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2018
  • Figure 3.1 Global IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 4.1 World IBD Drugs Market Shares by Drug Class (%), 2018
  • Figure 4.2 Global IBD Drug Market Forecast ($m), 2019-2029
  • Figure 4.3 World IBD Drugs Market Shares by Drug Class (%), 2029
  • Figure 4.4 Global Biologics Forecast for IBD Market ($m), 2019-2029
  • Figure 4.5 Global Aminosalicylates Forecast for IBD Market ($m), 2019-2029
  • Figure 4.6 Global Antibiotics Forecast for IBD Market ($m), 2019-2029
  • Figure 4.7 Global Corticosteroids Forecast for IBD Market ($m), 2019-2029
  • Figure 4.8 Global Immunomodulators Forecast for IBD Market ($m), 2019-2029
  • Figure 5.1 World Humira Revenue Forecast ($m), 2019-2029
  • Figure 5.2 World Remicade Forecast ($m), 2019-2029
  • Figure 5.3 World Cimzia Forecast ($m), 2019-2029
  • Figure 5.4 World Tysabri Forecast ($m), 2019-2029
  • Figure 5.5 World Asacol Forecast ($m), 2019-2029
  • Figure 5.6 World Pentasa Forecast ($m), 2019-2029
  • Figure 5.7 World Lialda Forecast ($m), 2019-2029
  • Figure 5.8 World Xifaxan Forecast ($m), 2019-2029
  • Figure 5.9 World Canasa Forecast ($m), 2019-2029
  • Figure 5.10 World Apriso Forecast ($m), 2019-2029
  • Figure 5.11 World Entyvio Forecast ($m), 2019-2029
  • Figure 5.12 World Simponi Forecast ($m), 2019-2029
  • Figure 5.13 World Uceris Forecast ($m), 2019-2029
  • Figure 6.1 World Inflammatory Bowel Disease by Distribution Channel Forecast, 2019-2029
  • Figure 7.1 Global IBD Drug Market by Leading Country (%), 2019
  • Figure 7.2 Global IBD Drug Market by Leading Country (%), 2029
  • Figure 7.3 US IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.4 US IBD Drug Market Forecast by Indication Forecast, ($m), 2019-2029
  • Figure 7.5 US IBD Drug Market by Drug Class Forecast, ($m), 2019-2029
  • Figure 7.6 US IBD Drug Market by Distribution Channel Forecast, ($m), 2019-2029
  • Figure 7.7 Japanese IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.8 Japanese IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.9 Japanese IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.10 Japanese IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.11 EU5 IBD Drug Market Forecasts ($m), 2019-2029
  • Figure 7.12 German IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.13 German IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.14 German IBD Drug Market Forecast by Drug Class($m), 2019-2029
  • Figure 7.15 German IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.16 French IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.17 French IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.18 French IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.19 French IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.20 UK IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.21 UK IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.22 UK IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.23 UK IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.24 Spanish IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.25 Spanish IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.26 Spanish IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.27 Spanish IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.28 Italian IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.29 Italian IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.30 Italian IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.31 Italian IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.32 BRIC IBD Drug Market Forecasts ($m), 2019-2029
  • Figure 7.33 Brazilian IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.34 Brazilian IBD Drug Market Forecast by Indication ($m), 2019-2029
  • Figure 7.35 Brazilian IBD Drug Market Forecast by Drug Class ($m), 2019-2029
  • Figure 7.36 Brazilian IBD Drug Market Forecast by Distribution Channel ($m), 2019-2029
  • Figure 7.37 Russian IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.38 Indian IBD Drug Market Forecast ($m), 2019-2029
  • Figure 7.39 Chinese IBD Drug Market Forecast ($m), 2019-2029
  • Figure 10.1 AbbVie Assets (Immunology, Hematologic Oncology, Neuroscience, Virology and Targeted Opportunities) - Marketed and Pipeline 2018
  • Figure 10.2 AbbVie Assets (Immunology) - Marketed and Pipeline 2018
  • Figure 10.3 AbbVie Deals and Partnerships 2011 - 2017
  • Figure 10.4 Janssen Assets - Marketed and Pipeline 2018
  • Figure 10.5 Janssen - Deals and Partnerships 2011 - 2017
  • Figure 10.6 Janssen - Inflammatory Bowel Disease Pipeline Products 2018-2019
  • Figure 10.7 Allergan Assets - Marketed and Pipeline 2018
  • Figure 10.8 Allergan - Deals and Partnerships 2011 - 2018
  • Figure 10.9 Takeda - Major Areas: ~75% of Total Sales Concentrated in Five Areas
  • Figure 10.10 Takeda Assets - Marketed and Pipeline 2018
  • Figure 10.11 Shire - Deals and Partnerships 2011 - 2018
  • Figure 10.12 Pfizer Assets - Marketed and Pipeline 2018
  • Figure 10.13 Novartis AG Assets - Marketed and Pipeline 2018
  • Figure 10.14 UCB Pharma A.S. Assets - Marketed and Pipeline 2018

Companies Listed

  • 4SC
  • Abbott Laboratories
  • AbbVie
  • Ablynx
  • Actavis
  • Active Biotech
  • Ajinomoto
  • Alfasigma Group
  • Allergan
  • Almirall
  • Amgen
  • Aptalis Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Athersys
  • Atlantic Healthcare
  • Avaxia Biologics
  • BioLineRx
  • Biosafe
  • Boehringer Ingelheim
  • Calico
  • Celgene
  • Celltrion
  • Centocor Ortho Biotech
  • Cipla
  • Coherus Biosciences
  • Coronado Biosciences
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma
  • Eddingpharm
  • Elan Pharmaceuticals
  • Epirus Biopharmaceuticals
  • Ferring
  • Forest Laboratories
  • Galapagos
  • Giaconda
  • Google
  • Harbor Biosciences
  • Hospira
  • Immunic
  • InDex Pharmaceuticals
  • Infinity Pharmaceuticals
  • Isis Pharmaceuticals
  • Janssen Biotech
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd
  • LG Sciences
  • Lupin
  • MedImmune
  • Mochida
  • Mutare Health
  • Mylan Pharmaceuticals
  • Neovacs
  • Nisshin Kyorin
  • Nogra Pharma
  • NovaMedica
  • Novartis
  • Oncobiologics
  • Ortho Biotech
  • Osiris Therapeutics
  • Otsuka
  • Ovamed
  • Palau Pharma
  • Par Pharmaceuticals
  • Pendopharm
  • Perrigo
  • Pfenex
  • Pfizer
  • Pharmascience
  • Pluristem Therapeutics
  • Qu Biologics
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Receptos
  • RedHill Biopharma
  • Reliance Life Sciences
  • Roche
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Sequella
  • Shire Pharmaceuticals
  • Sigmoid Pharma
  • Soligenix
  • SonarMD
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • TiGenix
  • Toray Industries
  • Torrent Pharmaceuticals Ltd.
  • TxCell
  • UCB
  • Valeant
  • Warner Chilcott
  • Zeria Pharmaceutical
  • Zydus Cadila

List of Organisations Mentioned in the Report

  • American Gastroenterological Association (AGA)
  • Case Western Reserve University
  • Center for Human Disease Research, Leiden
  • Centrale Commissie Mensgebonden Onderzoek (CCMO)
  • Centres for Disease Control and Prevention (US)
  • Crohn's and Colitis Foundation of Canada
  • European Commission
  • European Crohn's and Colitis Organisation (ECCO)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Georgia State University
  • German Society of Gastroenterology (DGVS)
  • Hebrew University of Jerusalem
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Karolinska Institute
  • National Health Service (UK NHS)
  • National Institute for Health and Care Excellence (UK NICE)
  • National Institutes of Health (US NIH)
  • Servicio Sanitario Nazionale (SSN, Italy)
  • The Crohn's and Colitis UK Foundation
  • The European Federation of Crohn's and Ulcerative Colitis Associations
  • The Scripps Research Institute (TSRI)
  • The University of Iowa
目次
Product Code: PHA0441

The global inflammatory bowel diseases (IBD) drug market is estimated at $7.2bn in 2018. Biologic therapies held 65% share of the IBD market in 2018 and is estimated to grow at a CAGR of 3.6% in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 245-page report you will receive 119 tables and 77 figures - all unavailable elsewhere.

The 245-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029
  • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Indication:
  • Crohn's Disease
  • Ulcerative Colitis
  • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Distribution Channel:
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2019-2029 by Drug Class:
  • Biologics
  • Aminosalicylates
  • Antibiotics
  • Corticosteroids
  • Immunomodulators

image1

  • Revenue forecast from 2019-2029 for the selected leading products:
  • Apriso
  • Asacol
  • Canasa/Salofalk
  • Cimzia
  • Entyvio
  • Humira
  • Lialda
  • Pentasa
  • Remicade
  • Simponi
  • Tysabri
  • Uceris
  • Xifaxan
  • Revenue forecasts from 2019-2029 for these national markets segmented by indication, drug class and distribution channel:
  • US
  • Japan
  • Germany, France, UK, Spain and Italy (EU5)
  • Brazil, Russia, India and China (BRIC)
  • Discussions on research and development , including drug candidates in these classes:
  • Interleukin (IL) inhibitors
  • Cell-adhesion molecule (CAM) inhibitors
  • TNF-alpha inhibitors
  • Stem cell therapies
  • JAK inhibitors
  • Toll-like receptor agonists
  • Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry:
  • AbbVie
  • Allergan
  • Biogen
  • Celgene Corporation
  • Gilead Sciences
  • Janssen
  • Novartis
  • Pfizer
  • Roche
  • Takeda
  • UCB Pharma S.A.
  • Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT) . It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.
  • Key Questions Answered by This Report:
  • How is the inflammatory bowel disease drugs industry and market evolving?
  • What is the technological and commercial potential of those IBD therapies from 2019?
  • What sales values are possible at overall world, submarket, product and national levels?
  • What are the market shares of its segments and how will they change to 2029?
  • How much will those submarkets' revenues expand from 2019 to 2029?
  • Which medicines will dominate and how high can leading brands' revenues go from 2019 to 2029? Which products will gain in sales and which will lose market shares?
  • What forces stimulate and restrain that industry and market from 2019 to 2029?
  • How will political and economic issues affect that overall sector and its submarkets?
  • How will relative shares of national markets change by 2029, and which region will lead the world then? How high will leading national revenues go?
  • Who form the leading companies, what do they offer, and what are their commercial prospects?

Table of Contents

1. Report Overview

  • 1.1 World IBD Drugs Market: Overview of Findings
  • 1.2 Why You Should Read This Report
  • 1.3 How the Study Delivers
  • 1.4 Main Questions Covered in the Analysis
  • 1.5 Who is this Report For?
  • 1.6 Methods of Research and Analysis
    • 1.6.1 Primary Research
    • 1.6.2 Secondary Research
    • 1.6.3 Market Evaluation and Forecasting Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market

  • 2.1 What is Inflammatory Bowel Disease (IBD)?
  • 2.2 Classification of IBD
  • 2.3 Symptoms and Diagnosis of IBD
  • 2.4 Multifactorial Causes of IBD
  • 2.5 How Common is IBD?
  • 2.6 What Are the Treatment Options for IBD?
    • 2.6.1 Aminosalicylates - The Most Common Therapy
    • 2.6.2 Antibiotics - Will There Be Any Supporting Evidence Soon?
    • 2.6.3 Corticosteroids - Uptake from Uceris?
    • 2.6.4 Immunomodulators - Slow to Act?
    • 2.6.5 Monoclonal Antibodies - Not Cost-effective?
  • 2.7 Treatment Goals for IBD - Treat-to-Target Approach?
  • 2.8 Treatment Algorithm - is Top-Down Approach the Future Direction?
  • 2.9 Management of Inflammatory Bowel Disease - 2018

3. Global Inflammatory Bowel Diseases Drug Market by Indication, 2019-2029

4. Global Inflammatory Bowel Diseases Drug Market by Drug Class, 2019-2029

  • 4.1 The Inflammatory Bowel Disease Market in 2017 and 2018
  • 4.2 Forecast 2019-2029: Impacted by Biosimilars?
  • 4.3 Biologic Therapies Forecast 2019-2029 - Driving the Market
  • 4.4 Aminosalicylates Forecast 2019-2029: The steady decline
  • 4.5 Antibiotics Forecast 2019-2029: Growing Despite Challenges
  • 4.6 Corticosteroids Forecast 2019-2029: Driven by Uceris
  • 4.7 Immunomodulators Forecast 2019-2029 - Will Grow at Moderate Pace

5. Market Prospects for Leading IBD Drugs, 2019-2029

  • 5.1 Humira (AbbVie) - Growing in the First Half of Forecast Period
    • 5.1.1 Humira: Forecast and Analysis, 2019-2029
  • 5.2 Remicade (Janssen Biotech) - Will Slowly Be Eroded by Biosimilars
    • 5.2.1 Remicade: Forecast and Analysis, 2019-2029
  • 5.3 Cimzia (UCB) - How Will It Fare Against Biosimilars?
    • 5.3.1 Cimzia: Forecast and Analysis, 2019-2029
  • 5.4 Tysabri (Perrigo) - Still Protected by Patent
    • 5.4.1 Tysabri: Forecast and Analysis, 2019-2029
  • 5.5 Asacol (Allergan) - Threat from Generic Competition
    • 5.5.1 Asacol: Forecast and Analysis, 2019-2029
  • 5.6 Pentasa (Shire) - Differentiated by Its Delivery System
    • 5.6.1 Pentasa: Forecast and Analysis, 2019-2029
  • 5.7 Lialda (Shire) - Will Improved Compliance Increase Revenue?
    • 5.7.1 Lialda: Forecast and Analysis, 2019-2029
  • 5.8 Xifaxan (Valeant) - Still Growing Significantly
    • 5.8.1 Xifaxan: Forecast and Analysis, 2019-2029
  • 5.9 Canasa/ Salofalk (Allergan) - Will a Generic Competitor Soon Be Available?
    • 5.9.1 Canasa/Salofalk: Forecast and Analysis, 2019-2029
  • 5.10 Apriso (Valeant) - Challenger to Asacol?
    • 5.10.1 Apriso: Forecast and Analysis, 2019-2029
  • 5.11 Entyvio (Takeda Pharmaceuticals) - Driving the Biologics Segment
    • 5.11.1 Entyvio: Forecast and Analysis, 2019-2029
  • 5.12 Simponi (Janssen Biotech) - Rising Star for the Market?
    • 5.12.1 Simponi: Forecast and Analysis, 2019-2029
  • 5.13 Uceris (Valeant) - Meeting Patients' Needs with Its Delivery System
    • 5.13.1 Uceris: Forecast and Analysis, 2019-2029

6. Global Inflammatory Bowel Disease by Distribution Channel, 2019-2029

7. Leading National Markets: Sales Outlooks, 2019-2029

  • 7.1 IBD Drugs - Leading National Markets 2018
  • 7.2 The US IBD Drug Market, 2019-2029 - The World Leader
  • 7.3 The Japanese IBD Drug Market, 2019-2029 - Growing Significantly?
  • 7.4 The EU-5 IBD Drug Market, 2019-2029 - Driven by the UK
  • 7.5 IBD Drug Markets in BRIC Countries - Taking More Market Share

8. The R&D Pipeline for Inflammatory Bowel Disease

  • 8.1 Top Marketed and pipeline products - Launch dates and Patent expiry
  • 8.2 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
  • 8.3 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
    • 8.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
    • 8.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
    • 8.3.3 MEDI 7183/AMG 181 (AstraZeneca)
    • 8.3.4 Etrolizumab (Roche)
    • 8.3.5 PF-00547659 (Pfizer)
    • 8.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
    • 8.3.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
  • 8.4 TNF-a Inhibitors - a Specific Target
    • 8.4.1 AVX-470 (Avaxia Biologics)
    • 8.4.2 Ozoralizumab (ALX-0061, Ablynx)
  • 8.5 Stem Cell Therapies - Basis for a Cure?
    • 8.5.1 Ovasave (TxCell)
    • 8.5.2 MultiStem (Athersys and Pfizer)
    • 8.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
    • 8.5.4 Cx601 (TiGenix)
  • 8.6 JAK Inhibitors - New Target Pathway
    • 8.6.1 JNJ-54781532 (Janssen)
    • 8.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
  • 8.7 Toll-like Receptor Agonists
    • 8.7.1 BL-7040 (BioLineRX)
    • 8.7.2 Kappaproct (InDex Pharmaceuticals)
  • 8.8 Other Classes of Agent
    • 8.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
    • 8.8.2 GLPG0974 (Galapagos)
    • 8.8.3 RPC1063 (Receptos/now Celgene)
    • 8.8.4 SGX203 (Soligenix)
    • 8.8.5 Mongersen (GED-0301, Celgene)
    • 8.8.6 Tetomilast (OPC-6535, Otsuka)
    • 8.8.7 Laquinimod (Active Biotech)
    • 8.8.8 RHB-104 (RedHill Biopharma)
    • 8.8.9 Ozanimod (Celgene)
    • 8.8.10 GED-0301 (Celgene)
  • 8.9 Biosimilar Candidates - Promising Competitors of Leading Biologics
    • 8.9.1 Adalimumab Biosimilars
    • 8.9.2 Infliximab Biosimilars

9. Qualitative Analysis of the Inflammatory Bowel Disease Drug Industry and Market

  • 9.1 SWOT and STEP Analysis of the IBD Drugs Market
  • 9.2 What Factors Will Stimulate the IBD Market?
    • 9.2.1 Increasing Disease Incidence in Most National Markets
    • 9.2.2 Better Diagnosis
    • 9.2.3 Delivery Systems Improve Existing Drugs
    • 9.2.4 Biological Drugs - Driving the Market Significantly
    • 9.2.5 Socioeconomic Costs of IBD
  • 9.3 What Factors Will Restrain the Market?
    • 9.3.1 Lack of Understanding of Disease Aetiology
    • 9.3.2 Compliance - Frequent Dosing is Inconvenient
    • 9.3.3 Limitations of Biologics - Side Effect Profiles
    • 9.3.4 The Possible Development of Alternative Treatments
    • 9.3.5 Surgery - Treatment for Recalcitrant IBD
    • 9.3.6 Health Care Cost Containment

10. Leading Companies in the IBD Pharmaceuticals Market

  • 10.1 The Largest Companies by Revenue
    • 10.1.1 AbbVie
    • 10.1.2 Janssen Biotech
    • 10.1.3 Allergan plc
    • 10.1.4 Takeda Pharmaceuticals
    • 10.1.5 Pfizer
    • 10.1.6 Novartis AG
    • 10.1.7 UCB Pharma S.A.
    • 10.1.8 Biogen Inc.
    • 10.1.9 Gilead Sciences, Inc.
    • 10.1.10 Roche
    • 10.1.11 Celgene Corporation

11. Conclusions of the Study

  • 11.1 The IBD Drugs Market Will Expand from 2019 to 2029
  • 11.2 Aminosalicylates and Other Non-Biologic Treatments
  • 11.3 Biological Treatments Dominate the Market
  • 11.4 Improvements Needed in IBD Therapy
  • 11.5 Future IBD Treatments: R&D Efforts Look Promising
  • 11.6 The IBD Sector: Looking to the Future with Confidence

Appendices

  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top